Skip to main content

Peer Review reports

From: Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer’s perspective

Original Submission
23 Oct 2017 Submitted Original manuscript
17 Jan 2018 Reviewed Reviewer Report - Giorgio Lorenzo Colombo
21 Feb 2018 Reviewed Reviewer Report - Thuy Nguyen
7 Mar 2018 Author responded Author comments - Ping-Tee Tan
Resubmission - Version 2
7 Mar 2018 Submitted Manuscript version 2
Publishing
13 Mar 2018 Editorially accepted
27 Mar 2018 Article published 10.1186/s12885-018-4223-y

You can find further information about peer review here.

Back to article page